Please try another search
For the nine months ended 30 September 2018, Asterias Biotherapeutics Inc revenues decreased 82% to $703K. Net loss decreased 37% to $13.7M. Revenues reflect Grant income decrease from $3.7M to $0K. Lower net loss reflects Research and development - Balancing val decrease of 47% to $9.7M (expense), General and administrative - Other decrease of 28% to $4.8M (expense), Stock-based Compensation in R&D decrease of 45% to $1.1M (expense).
Period Ending: | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 |
---|---|---|---|---|
Total Revenue | 0.12 | 0.11 | 0.48 | 0.03 |
Gross Profit | 0.06 | 0.05 | 0.41 | 0.01 |
Operating Income | -5.36 | -5.55 | -5.12 | -8.55 |
Net Income | -4.45 | -6.98 | -2.31 | -6.55 |
Period Ending: | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 |
---|---|---|---|---|
Total Assets | 29.81 | 34.34 | 39.33 | 43.09 |
Total Liabilities | 5.31 | 6.27 | 6.32 | 9.55 |
Total Equity | 24.5 | 28.07 | 33 | 33.54 |
Period Ending: | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | -10.04 | -7.13 | -3.94 | -24.44 |
Cash From Investing Activities | 2.74 | 2.48 | 1.48 | 0.72 |
Cash From Financing Activities | 0.56 | 0.7 | -0.29 | 17.18 |
Net Change in Cash | -6.74 | -3.95 | -2.75 | -6.53 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review